Histone deacetylase inhibitor LBH589 radiosensitizes non-small cell lung cancer by inhibiting DNA repair

被引：0
|
作者：
Cuneo, K. C. [1 ]
Fu, A. [1 ]
Hallahan, D. E. [1 ]
Geng, L. [1 ]
机构：
[1] Vanderbilt Univ, Sch Med, Dept Radiat Oncol, Nashville, TN 37212 USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2006年 / 66卷 / 03期
关键词：
D O I：
10.1016/j.ijrobp.2006.07.314
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1049
引用
收藏
页码：S158 / S158
页数：1
相关论文
共 50 条
  • [31] Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor alpha (ER) gene expression without loss of DNA hypermethylation
    Zhou, Qun
    Atadja, Peter
    Davidson, Nancy E.
    CANCER BIOLOGY & THERAPY, 2007, 6 (01) : 64 - 69
  • [32] The prostate cancer blocking potential of the histone deacetylase inhibitor LBH589 is not enhanced by the multi receptor tyrosine kinase inhibitor TKI258
    Stefan Vallo
    Jens Mani
    Matthias Stastny
    Jasmina Makarević
    Eva Juengel
    Igor Tsaur
    Georg Bartsch
    Axel Haferkamp
    Roman A. Blaheta
    Investigational New Drugs, 2013, 31 : 265 - 272
  • [33] A drug interaction study between ketoconazole and panobinostat (LBH589), an orally active histone deacetylase inhibitor, in patients with advanced cancer
    DeJonge, M.
    Woo, M. M.
    Van der Biessen, D.
    Hamberg, P.
    Sharma, S.
    Chen, L. C.
    Myke, N.
    Zhao, L.
    Hirawat, S.
    Verweij, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [34] The histone deacetylase inhibitor, LBH589 blocks osteoclastogenesis, enhances osteoblast activity and reduces tumor burden in bone
    Lee, Michelle
    Labrinidis, Agatha
    Liapis, Vasilios
    Hay, Shelley
    Zinonos, Irene
    Butler, Lisa
    Ponomarev, Vladimir
    Findlay, David
    Evdokiou, Andreas
    CANCER RESEARCH, 2009, 69
  • [35] A phase I trial of the histone deacetylase inhibitor panobinostat (LBH589) and epirubicin in patients with solid tumor malignancies
    Moore, A. P.
    Thomas, S.
    Ryan, C. J.
    Jahan, T. M.
    DuBois, S. G.
    Chan, J. K.
    Thurn, K. T.
    Reinhert, A.
    Daud, A.
    Munster, P. N.
    EJC SUPPLEMENTS, 2010, 8 (07): : 130 - 131
  • [36] Phase I trial of the HDAC inhibitor LBH589 in combination with sorafenib in patients with renal cell carcinoma, non-small cell lung cancer and soft tissue sarcomas.
    Butler, Charles Mackie
    Laboccetta, Lydia T.
    Brisendine, Alan
    Keane, Thomas E.
    Sherman, Carol Arthur
    Drabkin, Harry A.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [37] A novel therapeutic combination with synergistic antitumor activity in colon cancer: The dual tyrosine kinase inhibitor lapatinib and the histone deacetylase inhibitor LBH589
    LaBonte, Melissa J.
    Wilson, Peter M.
    El-Khoueiry, Anthony
    Lenz, Heinz -Josef
    Ladner, Robert D.
    CANCER RESEARCH, 2010, 70
  • [38] Bevacizumab radiosensitizes non-small cell lung cancer xenografts by inhibiting DNA double-strand break repair in endothelial cells
    Gao, Hui
    Xue, Jianxin
    Zhou, Lin
    Lan, Jie
    He, Jiazhuo
    Na, Feifei
    Yang, Lifei
    Deng, Lei
    Lu, You
    CANCER LETTERS, 2015, 365 (01) : 79 - 88
  • [39] Gefitinib radiosensitizes non-small cell lung cancer cells by suppressing cellular DNA repair capacity
    Tanaka, T
    Munshi, A
    Hobbs, ML
    Meyn, RE
    RADIOTHERAPY AND ONCOLOGY, 2006, 78 : S74 - S75
  • [40] Gefitinib radiosensitizes non-small cell lung cancer cells by suppressing cellular DNA repair capacity
    Tanaka, Toshirnitsu
    Munshi, Anupama
    Brooks, Colin
    Liu, Jenny
    Hobbs, Marvette L.
    Meyn, Raymond E.
    CLINICAL CANCER RESEARCH, 2008, 14 (04) : 1266 - 1273
12345